Basic Information

Gene symbol S Synonyms E2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description spike glycoprotein

GTO ID GTC2963
Trial ID NCT05280158
Disease COVID-19
Altered gene S
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment mRNA-1273|Elasomeran|Spikevax
Location approved UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US
PhasePhase1|Phase2
Recruitment statusCompleted
TitlePhase I/II, Open-Label Dose-Finding Trial of High-Dose mRNA-1273 Booster for Lung Transplant Recipients
Year2022
CountryUnited States
Company sponsorUniversity of California, Los Angeles
Other ID(s)22-000192
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: mRNA-1273_dose level 1
Administration route intramuscular injection
Dosage mRNA-1273, 50 ug, one dose
Age Child, Adult, Older_Adult
Cohort2: mRNA-1273_dose level 2
Administration route intramuscular injection
Dosage mRNA-1273, 100 ug, one dose
Age Child, Adult, Older_Adult
Cohort3: mRNA-1273_dose level 3
Administration route intramuscular injection
Dosage mRNA-1273, 200 ug, one dose
Age Child, Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph